title: FDG-PET for evaluating the antitumor effect of intraarterial 3-bromopyruvate administration in a rabbit VX2 liver tumor model.
abstract: OBJECTIVE
  We wanted to investigate the feasibility of using FDG-PET for evaluating the antitumor effect of intraarterial administration of a hexokinase II inhibitor, 3-bromopyruvate (3-BrPA), in a rabbit VX2 liver tumor model.
  
  
  METHODS
  VX2 carcinoma was grown in the livers of ten rabbits. Two weeks later, liver CT was performed to confirm appropriate tumor growth for the experiment. After tumor volume-matched grouping of the rabbits, transcatheter intraarterial administration of 3-BrPA was performed (1 mM and 5 mM in five animals each, respectively). FDG-PET scan was performed the day before, immediately after and a week after 3-BrPA administration. FDG uptake was semiquantified by measuring the standardized uptake value (SUV). A week after treatment, the experimental animals were sacrificed and the necrosis rates of the tumors were calculated based on the histopathology.
  
  
  RESULTS
  The SUV of the VX2 tumors before treatment (3.87+/-1.51 [mean+/-SD]) was significantly higher than that of nontumorous liver parenchyma (1.72+/-0.34) (p < 0.0001, Mann-Whitney U test). The SUV was significantly decreased immediately after 3-BrPA administration (2.05+/-1.21) (p = 0.002, Wilcoxon signed rank test). On the one-week follow up PET scan, the FDG uptake remained significantly lower (SUV 1.41+/-0.73) than that before treatment (p = 0.002), although three out of ten animals showed a slightly increasing tendency for the FDG uptake. The tumor necrosis rate ranged from 50.00% to 99.90% (85.48%+/-15.87). There was no significant correlation between the SUV or the SUV decrease rate and the tumor necrosis rate in that range.
  
  
  CONCLUSIONS
  Even though FDG-PET cannot exactly reflect the tumor necrosis rate, FDG-PET is a useful modality for the early assessment of the antitumor effect of intraarterial administration of 3-BrPA in VX2 liver tumor.
authors.affiliation: Department of Radiology, Seoul National University College of Medicine, Institute of Radiation Medicine, Seoul National University Medical Research Center and Clinical Research Institute, Seoul National University Hospital, Seoul, Korea.
authors.forename: Hee Sun
authors.initials: HS
authors.lastname: Park
authors.forename: Jin Wook
authors.initials: JW
authors.lastname: Chung
authors.forename: Hwan Jun
authors.initials: HJ
authors.lastname: Jae
authors.forename: Young Il
authors.initials: YI
authors.lastname: Kim
authors.forename: Kyu Ri
authors.initials: KR
authors.lastname: Son
authors.forename: Min Jong
authors.initials: MJ
authors.lastname: Lee
authors.forename: Jae Hyung
authors.initials: JH
authors.lastname: Park
authors.forename: Won Jun
authors.initials: WJ
authors.lastname: Kang
authors.forename: Jung Hwan
authors.initials: JH
authors.lastname: Yoon
authors.forename: Hesson
authors.initials: H
authors.lastname: Chung
authors.forename: Kichang
authors.initials: K
authors.lastname: Lee
mesh_terms: D000818:Animals; D004195:Disease Models, Animal; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D005240:Feasibility Studies; D019788:Fluorodeoxyglucose F18; D007261:Infusions, Intra-Arterial; D007269:Injections, Intra-Arterial; D008114:Liver Neoplasms, Experimental / Q000000981:diagnostic imaging* / Q000188:drug therapy* / Q000473:pathology; D009336:Necrosis; D049268:Positron-Emission Tomography; D011768:Pyruvate Dehydrogenase Complex / Q000037:antagonists & inhibitors; D011773:Pyruvates / Q000494:pharmacology*; D011817:Rabbits; D019275:Radiopharmaceuticals
chemical_list: D004791:Enzyme Inhibitors; D011768:Pyruvate Dehydrogenase Complex; D011773:Pyruvates; D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18; C017092:bromopyruvate